Company: DHR
Filing Date: 2025-04-22
Form Type: 10-Q
Source: 0000313616-25-000088
Chunk: 68

Company: DANAHER CORP /DE/
Filing Date: 2025-04-22
Form: 10-Q
Item: Item 8
Chunk 68
---
 earnings (the “Fair Value Alternative”).  Additionally, the Company is a limited partner in partnerships that invest primarily in early-stage companies.  While the partnerships record these investments at fair value, the Company’s investments in the partnerships are accounted for under the equity method of accounting.  The investment gains (losses) include realized and unrealized gains and losses related to changes in the fair value of the Company’s investments in equity securities and the Company’s equity in earnings of the partnerships that reflect the changes in fair value of the investments of the partnerships, and related management fees and operating expenses.Gain on Sale of Product LineDuring the three-month period ended March 28, 2025, the Company divested a product line for a cash purchase price of $9 million and recognized a pretax gain on sale of $9 million ($7 million after-tax).  The divested product line generated revenues of approximately $50 million in the Diagnostics segment in 2024.  The divestiture of this product line did not represent a strategic shift with a major effect on the Company’s operations and financial results and therefore is not reported as a discontinued operation.

NOTE 8.  GOODWILL AND OTHER INTANGIBLE ASSETS 

The following is a rollforward of the Company’s goodwill ($ in millions):Balance, December 31, 2024$40,497 Adjustments due to finalization of purchase price allocations3 Foreign currency translation and other1,157 Balance, March 28, 2025$41,657 The carrying value of goodwill by segment is summarized as follows ($ in millions):March 28, 2025December 31, 2024Biotechnology$22,315 $21,437 Life Sciences12,505 12,305 Diagnostics6,837 6,755 Total$41,657 $40,497 The Company has not identified any “triggering” events which indicate an impairment of goodwill in 2025.  The Company has not identified any impairment triggers that resulted in impairments of intangible assets in the first quarter of 2025.  The Company will continue to review goodwill and other intangible assets for impairment when events or changes in circumstances, including evolving market conditions and regulatory environment, indicate related carrying amounts may not be recoverable.  During the three-month period ended March 28, 2025, the Company recorded a $15 million impairment related to a facility in the Biotechnology segment.

NOTE 9.